Skip to content

The comparison of the effect of bitter orange and ondansetron on treatment of nausea and vomiting of pregnancy

The comparison of the effect of bitter orange and ondansetron on treatment of nausea and vomiting in pregnant women between weeks 6 till 20 of pregnancy

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20140525017827N11
Enrollment
80
Registered
2021-08-14
Start date
2021-08-23
Completion date
Unknown
Last updated
2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nausea & vomiting in pregnancy. Vomiting of pregnancy, unspecified

Interventions

Intervention 1: Intervention group: Treatment of one group with bitter orange. Intervention 2: Intervention group: The other group with ondansetron.

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: gestational age between 6-20 weeks of pregnancy (according to a reliable LMP and ultrasound confirmation of the first trimester) Having mild to moderate nausea and vomiting without a need of hospitalization Singleton pregnancy with a live normal fetus Not having any known gastrointestinal disorder Without a history of smoking or drug use Lack of a known mental illness such as severe anxiety and depression Not having any known allergy or hypersensitivity to herbal medications

Exclusion criteria

Exclusion criteria: Severe nausea and vomiting needing hospitalization No acceptance for herbal medicine Having any other symptoms showing pathologic problems such as diarrhea Having any known gastrointestinal or any other systemic disorder or any drug use except common supplementation (folic acid)

Design outcomes

Primary

MeasureTime frame
Intensity of nausea and vomiting. Timepoint: Before start and two weeks later of treatment. Method of measurement: Visual analog scale.

Secondary

MeasureTime frame
Quality of life score. Timepoint: Before start and two weeks later of treatment. Method of measurement: Short Form 36 Health Survey (SF-36).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarrokh khani

Shiraz University of Medical Sciences

Farrokhkhani1368@gmail.com+98 71 3612 8258

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026